1 recruiting. 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
Follow POZ: new trials by email Literature Review of POZ trials Research Report on POZ
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma Pomalidomide, Orelabrutinib, Zuberitamab - Mantle Cell Lymphoma (MCL), POZ | Not applicable | Recruiting | Peking University Third Hospital | 34 | 2025-08-01 | 2025-12-02 |
Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
orelabrutinib (1) · pomalidomide (1)
Peking University Third Hospital (1)
China (1)